KOL Insight Archives | Page 3 of 5 | Report Store

Datamonitor Healthcare Type 2 Diabetes KOL Interview – US

In this discussion with a US KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.

October 12, 2018

Find out more

Datamonitor Healthcare Ulcerative Colitis KOL Interviews

$599.00

Datamonitor Healthcare interviewed two ulcerative colitis (UC) experts, one based in Italy and the other in the US, to gauge their views on approved and late-stage pipeline drugs, treatment challenges and unmet needs and the future treatment of UC.

August 18, 2017

Find out more

Datamonitor Meningococcal Vaccines KOL Interview

$599.00

Datamonitor interviewed an infectious diseases specialist based in the US Greater Washington DC area to determine this physician’s views on marketed and pipeline meningococcal vaccines.

July 12, 2016

Find out more

Datamonitor Schizophrenia KOL Interview

$599.00

On key factors effecting treatment: “First of all tolerability, because if the tolerability is not good then there will be no adherence. The second is efficacy, and the third one maybe is also whether the compound is also available as a depot. I think that is a major advantage if a drug, if an antipsychotic, is indeed available as a depot or as a long-acting injection (LAI).”

February 10, 2016

Find out more

Datamonitor Schizophrenia KOL Interview 2

$599.00

KOL believes that the available schizophrenia treatments that provide the most efficacy also have the highest side effects.

February 24, 2016

Find out more

Datapack – Pharmaprojects Pharma R&D Annual Review 2017

$1,999.00

This datapack presents the supporting data behind the seminal white paper, Pharma R&D Annual Review 2017. The white paper is available for free for Biomedtracker subscribers.

April 18, 2017

Find out more

Depression KOL Interview – US #1

$599.00

A US expert in the depression field dives into the treatment algorithm, critical unmet needs, and pipeline drugs such as SAGE-217 and AXS-05.

March 2, 2021

Find out more

Depression KOL Interview – US #2

$599.00

A US expert in the depression field dives into the treatment algorithm, critical unmet needs, and pipeline drugs such as SAGE-217 and AXS-05.

March 2, 2021

Find out more

Dermatology KOL Interview

$599.00

BioMedTracker – Dermatology KOL Interview In recent years, patients have become more comfortable with aesthetic dermatology procedures as they have become more widespread.

October 31, 2014

Find out more

Diffuse Large B-Cell Lymphoma (DLBCL) KOL Interview – UK

$599.00

A UK-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for DLBCL. Therapies discussed include Polivy, Monjuvi, Zynlonta, CD19-directed CAR-T therapy, and CD20-directed bispecific antibodies.

April 21, 2022

Find out more

Diffuse Large B-Cell Lymphoma (DLBCL) KOL Interview – US

$599.00

A US-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for DLBCL. Therapies discussed include Polivy, Monjuvi, Zynlonta, CD19-directed CAR-T therapy and CD20-directed bispecific antibodies.

April 21, 2022

Find out more

Drug Pricing and Market Access KOL Interview

$599.00

Expensive oncology treatments [PD-1 and upcoming CAR-T therapies] will continue to be covered by large insurers formularies, but access will be restricted according to NCCN guidelines.

February 1, 2016

Find out more

Dyslipidemia and Diabetes Reimbursement KOL Interview:

$599.00

Topics: Dyslipidemia and Diabetes Reimbursement PCSK9 Inhibitors, SGLT2/DPP4 Inhibitor FDCs, and Biosimilar Insulin

August 5, 2015

Find out more

Dyslipidemia KOL Insight Interview #1

$599.00

Discusses usage of PCSK9 and CETP inhibitors in various scenarios based on outcomes data

July 25, 2014

Find out more

Dyslipidemia KOL Insight Interview #2

$599.00

Discusses percent not meeting goal and projected usage of PCSK9 and CETP inhibitors in various scenarios based on outcomes data.

July 28, 2014

Find out more

Ebola KOL Interview #1

$599.00

So the history in Africa has been very extensive since the 1970s and outbreaks in those countries havehappened sporadically over the last 40 years. Here in US, right, this is our first case of anyone being sick with Ebola, and there are a number of people who have actually come into the country.

November 2, 2014

Find out more

Ebola KOL Interview #3

$599.00

Ebola KOL Interview #3

December 2, 2014

Find out more

ECLIPSE Psoriasis Pulse Survey

$599.00

This 11-question pulse survey of 74 dermatologists practicing throughout the US and Europe asks respondents their thoughts on results from the ECLIPSE study

January 31, 2019

Find out more

Epilepsy KOL Interview – US, West

$599.00

A US key opinion leader (KOL) discusses the epilepsy treatment landscape, including new market entrant Epidiolex, and provides their perspective on late-phase pipeline anti-epileptic drugs such as Fintepla.

February 18, 2019

Find out more

Follicular Lymphoma KOL Interview

$599.00

“When people need therapy (for advanced stage Follicular Lymphoma), there’s a whole gamut. If they have relatively low volume disease, one option, which unfortunately in the community I would say is underutilized, is single-agent rituximab.”

February 3, 2016

Find out more

Follicular Lymphoma KOL Interview – UK

$599.00

This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for follicular lymphoma. Disease stratification by staging and expression as well as unmet needs are also discussed. Key assets highlighted include Rituxan, Revlimid, Gazyva, Yescarta, Imbruvica, Kymriah, Tazverik, and mosunetuzumab.

June 11, 2021

Find out more

Follicular Lymphoma KOL Interview – US

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for follicular lymphoma. Disease stratification by staging and expression, as well as unmet needs, are also discussed. Key assets highlighted include Rituxan, Revlimid, Gazyva, Yescarta, Imbruvica, Kymriah, and mosunetuzumab.

July 16, 2021

Find out more

Gastric Cancer KOL Interview – US

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for gastric cancer. Disease stratifications by staging and origin of the primary tumor, as well as unmet needs, are also discussed. Key therapies highlighted include Opdivo, Yervoy, Keytruda, Cyramza, Herceptin, and Enhertu.

August 5, 2020

Find out more

GLP-1 Pulse Survey

$599.00

This survey of US primary care physicians (n=10) and endocrinologists (n=10) was undertaken to evaluate the impact of GLP-1 agonists if they were to be introduced in the Diabetes market.

August 25, 2014

Find out more

Head and Neck Cancer KOL Interview – UK

$599.00

This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for head and neck cancer. Disease stratification by staging and origin of the primary tumor, as well as unmet needs, are also discussed. Key pipeline assets highlighted include Imfinzi, Bavencio, tremelimumab, and Tecentriq.

April 14, 2020

Find out more

Head and Neck Cancer KOL Interview – US, Southeast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for head and neck cancer. Disease stratification by staging and origin of the primary tumor, as well as unmet needs, are also discussed. Key pipeline assets highlighted include Imfinzi, Bavencio, tremelimumab, and Tecentriq.

April 14, 2020

Find out more

Hemophilia KOL Interview – UK

$599.00

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed drugs, and late-phase pipeline therapies for hemophilia, including alternative coagulation promoters and gene therapies. Unmet needs are also discussed. The main marketed products covered include Hemlibra, Advate, BeneFIX, and Eloctate, and key pipeline assets highlighted are valoctocogene roxaparvovec (valrox), fitusiran, and concizumab.

March 20, 2020

Find out more

Hemophilia KOL Interview – US, Southeast

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed drugs, and late-phase pipeline therapies for hemophilia, including alternative coagulation promoters and gene therapies. Unmet needs are also discussed. The main marketed products covered include Hemlibra, Advate, and BeneFIX, and key pipeline assets highlighted are valoctocogene roxaparvovec (valrox), fitusiran, and concizumab.

March 20, 2020

Find out more

HER2+ Breast Cancer KOL Interview – UK

$599.00

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HER2+ breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include Enhertu, tucatinib, margetuximab, and the subcutaneous fixed-dose combination of Herceptin and Perjeta.

March 3, 2020

Find out more

HER2+ Breast Cancer KOL Interview – US, West Coast

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HER2+ breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include tucatinib, margetuximab, Onzeald, SYD985, and the subcutaneous fixed-dose combination of Herceptin and Perjeta.

March 3, 2020

Find out more

HIV Pre-Exposure Prophylaxis (HIV PrEP) KOL Interview – US #1

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HIV PrEP. Drug pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include islatravir and cabotegravir.

August 10, 2021

Find out more

HIV Pre-Exposure Prophylaxis (HIV PrEP) KOL Interview – US #2

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HIV PrEP. Drug pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include islatravir and cabotegravir.

August 10, 2021

Find out more

Human Papillomavirus (HPV) KOL Interview – Italy

$599.00

A European-based key opinion leader (KOL) provides insights into prescribing trends, marketed vaccines, and vaccination coverage rates, as well as commentary on vaccination strategies in different markets. The marketed vaccines discussed include Cervarix, Gardasil, and Gardasil 9.

January 3, 2020

Find out more

Human Papillomavirus (HPV) KOL Interview – US, Midwest

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing trends, marketed vaccines, and vaccination coverage rates, as well as commentary on vaccination strategies in different markets. The marketed vaccines discussed include Cervarix, Gardasil, and Gardasil 9.

January 3, 2020

Find out more

Inflammatory Bowel Disease (IBD) KOL Interview – US

$599.00

A US gastroenterology expert dives into the treatment algorithm, critical unmet needs, and pipeline drugs for IBD, such as the Janus kinase inhibitors and sphingosine 1-phosphate (S1P) modulators.

March 1, 2021

Find out more

Inpatient Infections Pulse

$599.00

We conducted a survey of 20 infectious diseases specialists to evaluate current drug usage for the treatment of selected severe/inpatient infections and gauge physician interest in new drugs.

October 8, 2014

Find out more

Intersection Between Tech and Pharma KOL Interview

$599.00

Given the rapid change in the healthcare industry over the last few years, it is no surprise that we are starting to see more non-traditional healthcare partnerships, specifically with big tech companies.

January 12, 2016

Find out more

Key Questions in Immuno-Oncology

$1,099.00

This KOL survey answers key questions about current immunotherapy treatments and future trends in the immuno-oncology space.

August 8, 2018

Find out more

Leukemia KOL Insight and Pulse Survey Bundle

$1,099.00

The second-generation TKIs dasatinib and nilotinib are increasingly being used as frontline therapy for CML; this expert gives imatinib only to patients with co-morbidities.

September 8, 2017

Find out more

Macitenan for Pulmonary Arterial Hypertension

$89.00

Macitentan is a novel dual endothelin receptor antagonist (ERA)

showing sustained receptor occupancy

March 1, 2014

Find out more

Major Depressive Disorder KOL Interview – UK

$599.00

A UK key opinion leader (KOL) provides insight into the critical unmet needs in the depression market, along with future trends. Key late-phase pipeline drugs for major depressive disorder and post-partum depression are covered, with particular focus on Johnson & Johnson’s esketamine.

December 19, 2018

Find out more

MDS/AML KOL Interview

$599.00

Highlights More specific, next-generation FLT3 inhibitors may not have an anti-leukemic benefit over agents with broader TKI activity (such as sorafenib, AMGN), but they may not have as severe myelosuppressive effects. Although the kinase inhibitor rigosertib (ONTX) had poor Phase III results in MDS and AML, the subgroup of patients with primary HMA failure may […]

April 9, 2015

Find out more

Melanoma KOL Interview – US #1

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for melanoma. Treatment strategies split by disease stage, as well as unmet needs, are also discussed. Key pipeline assets highlighted include lifileucel, seviprotimut-L, Lenvima, and TAVO.

February 25, 2022

Find out more

Melanoma KOL Interview – US #2

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for melanoma. Treatment strategies split by disease stage, as well as unmet needs, are also discussed. Key pipeline assets highlighted include lifileucel, seviprotimut-L, Lenvima, and TAVO.

February 25, 2022

Find out more

Multiple Myeloma KOL Interview – UK

$599.00

This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for multiple myeloma. Drug adverse events and UK market access issues are also discussed. Key therapies highlighted include Darzalex, Venclexta, Xpovio, Ygalo, Blenrep, and BCMA-targeted CAR-T therapies.

May 15, 2020

Find out more